MoneyWorks4Me

Lupin gets non-exclusive license from TB Alliance to manufacture anti-TB drug pretomanid

06 Sep 2021 Evaluate

Lupin has been granted non-exclusive license from TB Alliance to manufacture the anti-TB drug pretomanid as part of the three-drug ‘BPaL’ regimen. Lupin intends to commercialize the antituberculosis (TB) medicine in approximately 140 countries and territories, including many of the highest TB burden countries around the world. 

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..